Platelet-rich plasma therapy is based on platelets' ability to speed up the body's natural recovery processes. The more platelets used in PRP injections, the more effective this treatment will be. The body can benefit from autologous platelet-rich plasma in a number of ways, including faster wound healing, increased cell regrowth, and the release of anti-inflammatory cytokines.
This is possible because of the anticoagulant buffy layer, which collects most platelets and neutrophils after centrifugation. The overall platelet count for PRP treatment will be lower if the PRP centrifuge equipment is unable to collect blood components from the buffy layer.
This could lead to platelet-poor plasma, a PRP product with a high number of leukocytes, stem cell deposits, and a lower concentration of platelets, being used in PRP therapy. The amount of platelet-rich plasma that can be used in PRP therapy can be decreased by using platelet-poor plasma.
Even though the blood components such as red blood cells, white blood cells, and other blood components are removed from the final PRP samples, the PRP treatment requires a large number of autologous platelets to ensure proper regrowth and healing.
This is possible only if the autologous plasma with high platelets has sufficient platelets. An autologous blood transfusion is generally easier for patients because there is less chance that their bodies will reject the treatment. However, PRP therapy has a specific goal: to infuse enough platelets to stimulate healing.